These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21098317)

  • 41. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
    Beer TM; Bergenstock M; Birt K; Higano CS
    Clin Genitourin Cancer; 2007 Jun; 5(5):329-33. PubMed ID: 17645830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
    Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
    Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.
    Nagel S; Kellner O; Engel-Riedel W; Guetz S; Schumann C; Gieseler F; Schuette W
    Clin Lung Cancer; 2011 Jan; 12(1):62-9. PubMed ID: 21273182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies.
    Hedenus M; Hansen S; Taylor K; Arthur C; Emmerich B; Dewey C; Watson D; Rossi G; Osterborg A;
    Br J Haematol; 2002 Oct; 119(1):79-86. PubMed ID: 12358906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
    Gascón P; Nagarkar R; Šmakal M; Syrigos KN; Barrios CH; Sánchez JC; Zhang L; Henry DH; Gordon D; Hirsh V; Kubota K; Orlov S; Thomas G; Steinmetz T; Kang JH; Tomita DK; Fleishman AN; Park JK; De Oliveira Brandao C
    J Thorac Oncol; 2020 Feb; 15(2):190-202. PubMed ID: 31629060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
    Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH
    Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A;
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Study of effectiveness of 3 schedules of administration of erythropoietic colony-stimulating factors in anemic patients under chemotherapy for solid or hematology malignancy].
    Pontón Sivillá JL; Feliu Frasnedo E; Modamio Charles P; Mariño Hernández EL; Font Pous A; Lezcano Rubio C; Ribera Santasusana JM; Bonafont Pujol X
    Med Clin (Barc); 2008 Oct; 131(12):447-51. PubMed ID: 18928734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Darbepoetin alpha as treatment for anemia in patients receiving chemotherapy: a single-center experience.
    Bartsch R; Wenzel C; Sevelda U; Hussian D; Pluschnig U; Locker GJ; Mader R; Zielinski CC; Steger GG
    Anticancer Drugs; 2005 Jul; 16(6):617-20. PubMed ID: 15930888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.
    Noronha V; Joshi A; Patil VM; Banavali SD; Gupta S; Parikh PM; Marfatia S; Punatar S; More S; Goud S; Nakti D; Prabhash K
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e129-e137. PubMed ID: 28849623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.